Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. [electronic resource]
Producer: 20120523Description: CD007743 p. digitalISSN:- 1469-493X
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antiviral Agents -- adverse effects
- Cystic Fibrosis -- complications
- Humans
- Infant
- Palivizumab
- Pseudomonas Infections -- epidemiology
- Pseudomonas aeruginosa
- Randomized Controlled Trials as Topic
- Respiratory Syncytial Virus Infections -- drug therapy
No physical items for this record
Publication Type: Journal Article; Review; Systematic Review
There are no comments on this title.
Log in to your account to post a comment.